WO2009113828A2 - Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid - Google Patents
Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid Download PDFInfo
- Publication number
- WO2009113828A2 WO2009113828A2 PCT/KR2009/001256 KR2009001256W WO2009113828A2 WO 2009113828 A2 WO2009113828 A2 WO 2009113828A2 KR 2009001256 W KR2009001256 W KR 2009001256W WO 2009113828 A2 WO2009113828 A2 WO 2009113828A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- radical
- hydrido
- formula
- independently selected
- Prior art date
Links
- 108091093037 Peptide nucleic acid Proteins 0.000 title claims abstract description 156
- 108020004707 nucleic acids Proteins 0.000 title abstract description 31
- 102000039446 nucleic acids Human genes 0.000 title abstract description 31
- 150000007523 nucleic acids Chemical class 0.000 title abstract description 30
- 230000035515 penetration Effects 0.000 title abstract description 22
- -1 deuterido Chemical group 0.000 claims description 109
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 52
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 38
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 36
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 34
- 125000001145 hydrido group Chemical group *[H] 0.000 claims description 32
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 28
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 27
- 229940104302 cytosine Drugs 0.000 claims description 25
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 24
- 229930024421 Adenine Natural products 0.000 claims description 23
- 229960000643 adenine Drugs 0.000 claims description 23
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 125000003277 amino group Chemical group 0.000 claims description 17
- 229940113082 thymine Drugs 0.000 claims description 17
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical class O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 14
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical class [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 claims description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 150000003254 radicals Chemical class 0.000 claims description 14
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 13
- 125000003107 substituted aryl group Chemical group 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 229940035893 uracil Drugs 0.000 claims description 11
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
- 125000005647 linker group Chemical group 0.000 claims description 8
- 239000011593 sulfur Substances 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 7
- 125000004104 aryloxy group Chemical group 0.000 claims description 6
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 230000014509 gene expression Effects 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000027455 binding Effects 0.000 abstract description 26
- 210000004027 cell Anatomy 0.000 description 71
- 238000002360 preparation method Methods 0.000 description 46
- 239000000243 solution Substances 0.000 description 45
- 238000005160 1H NMR spectroscopy Methods 0.000 description 44
- 108020004414 DNA Proteins 0.000 description 40
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 36
- 239000007787 solid Substances 0.000 description 36
- 239000000178 monomer Substances 0.000 description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- 230000000692 anti-sense effect Effects 0.000 description 28
- 230000002829 reductive effect Effects 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 27
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 22
- 239000011541 reaction mixture Substances 0.000 description 22
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 21
- 239000012044 organic layer Substances 0.000 description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
- 108091034117 Oligonucleotide Proteins 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 238000004440 column chromatography Methods 0.000 description 15
- 239000006260 foam Substances 0.000 description 15
- 108020004635 Complementary DNA Proteins 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- 238000010804 cDNA synthesis Methods 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 12
- 239000010410 layer Substances 0.000 description 12
- 239000004471 Glycine Substances 0.000 description 11
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000004624 confocal microscopy Methods 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 0 C[n]1c(N=C(NC*N(*)*)NC2=O)c2nc1 Chemical compound C[n]1c(N=C(NC*N(*)*)NC2=O)c2nc1 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
- 125000006626 methoxycarbonylamino group Chemical group 0.000 description 9
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 8
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 8
- 108010010705 glutarylphenylalanine-4-nitroanilide Proteins 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 230000003595 spectral effect Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- WVBHURHBQVNIHH-UHFFFAOYSA-N tert-butyl n-(2-but-3-ynoxyethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCOCCC#C WVBHURHBQVNIHH-UHFFFAOYSA-N 0.000 description 8
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical group NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- WMZTYIRRBCGARG-UHFFFAOYSA-N 2-azaniumyl-5-(4-nitroanilino)-5-oxopentanoate Chemical compound OC(=O)C(N)CCC(=O)NC1=CC=C([N+]([O-])=O)C=C1 WMZTYIRRBCGARG-UHFFFAOYSA-N 0.000 description 6
- 238000000942 confocal micrograph Methods 0.000 description 6
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 238000001243 protein synthesis Methods 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 5
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 5
- 108700011259 MicroRNAs Proteins 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 239000000074 antisense oligonucleotide Substances 0.000 description 5
- 238000012230 antisense oligonucleotides Methods 0.000 description 5
- 230000003915 cell function Effects 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 238000013375 chromatographic separation Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000001638 lipofection Methods 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 239000002679 microRNA Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 238000004007 reversed phase HPLC Methods 0.000 description 5
- CAZDFIVLCCIPEA-UHFFFAOYSA-N tert-butyl n-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propyl]-n-prop-2-ynylcarbamate Chemical compound CC(C)(C)OC(=O)NCCCN(CC#C)C(=O)OC(C)(C)C CAZDFIVLCCIPEA-UHFFFAOYSA-N 0.000 description 5
- GEGLCBTXYBXOJA-UHFFFAOYSA-N 1-methoxyethanol Chemical compound COC(C)O GEGLCBTXYBXOJA-UHFFFAOYSA-N 0.000 description 4
- IZGFERLHOCMZQF-UHFFFAOYSA-N 2-(10h-phenoxazin-1-yloxy)ethanamine Chemical group O1C2=CC=CC=C2NC2=C1C=CC=C2OCCN IZGFERLHOCMZQF-UHFFFAOYSA-N 0.000 description 4
- 108020004394 Complementary RNA Proteins 0.000 description 4
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 108010081734 Ribonucleoproteins Proteins 0.000 description 4
- 102000004389 Ribonucleoproteins Human genes 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- VCTPNEXIJVZGCQ-UHFFFAOYSA-N benzyl n-[n-phenylmethoxycarbonyl-n'-(2-prop-2-ynoxyethyl)carbamimidoyl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC(NCCOCC#C)=NC(=O)OCC1=CC=CC=C1 VCTPNEXIJVZGCQ-UHFFFAOYSA-N 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 239000003184 complementary RNA Substances 0.000 description 4
- 150000004985 diamines Chemical class 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 4
- 101150024228 mdm2 gene Proteins 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical compound NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108090000189 Neuropeptides Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- QSNHRCZHENQCLL-UHFFFAOYSA-N ethyl 2-[2-(1,3-benzothiazol-2-ylsulfonylamino)ethylamino]acetate Chemical compound C1=CC=C2SC(S(=O)(=O)NCCNCC(=O)OCC)=NC2=C1 QSNHRCZHENQCLL-UHFFFAOYSA-N 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 108091060283 mipomersen Proteins 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 210000003705 ribosome Anatomy 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- FPQMTWQFFRTHQP-ZCFIWIBFSA-N (2r)-2-(2-aminoethylamino)-5-(diaminomethylideneamino)pentanoic acid Chemical compound NCCN[C@@H](C(O)=O)CCCNC(N)=N FPQMTWQFFRTHQP-ZCFIWIBFSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- ONXCBJOMYNPZNI-UHFFFAOYSA-N 2-bromo-3,7-dihydropurin-6-one Chemical compound N1C(Br)=NC(=O)C2=C1N=CN2 ONXCBJOMYNPZNI-UHFFFAOYSA-N 0.000 description 2
- WIEATFFSFYPBQD-UHFFFAOYSA-N 2-chloro-3,7-dihydropurin-6-one Chemical compound N1C(Cl)=NC(=O)C2=C1N=CN2 WIEATFFSFYPBQD-UHFFFAOYSA-N 0.000 description 2
- HBJGQJWNMZDFKL-UHFFFAOYSA-N 2-chloro-7h-purin-6-amine Chemical compound NC1=NC(Cl)=NC2=C1NC=N2 HBJGQJWNMZDFKL-UHFFFAOYSA-N 0.000 description 2
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Substances CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 108010017842 Telomerase Proteins 0.000 description 2
- 150000000475 acetylene derivatives Chemical group 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- ICFSDLPZJDDPHP-UHFFFAOYSA-M benzyl 3-methylimidazol-3-ium-1-carboxylate;trifluoromethanesulfonate Chemical compound [O-]S(=O)(=O)C(F)(F)F.CN1C=C[N+](C(=O)OCC=2C=CC=CC=2)=C1 ICFSDLPZJDDPHP-UHFFFAOYSA-M 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- TZRFSLHOCZEXCC-HIVFKXHNSA-N chembl2219536 Chemical compound N1([C@H]2C[C@@H]([C@H](O2)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C(C)=C2)=O)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2CO)N2C3=C(C(NC(N)=N3)=O)N=C2)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(NC(=O)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP(O)(=O)OC[C@H]2O[C@H](C[C@@H]2SP(O)(=O)OC[C@H]2O[C@H](C[C@@H]2SP(O)(=O)OC[C@H]2O[C@H](C[C@@H]2SP(O)(=O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OCCOC)SP(O)(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP(O)(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C3=NC=NC(N)=C3N=C2)OCCOC)SP(O)(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP(O)(=O)OC[C@H]2[C@H](O)[C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)C=C(C)C(N)=NC1=O TZRFSLHOCZEXCC-HIVFKXHNSA-N 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 238000001254 matrix assisted laser desorption--ionisation time-of-flight mass spectrum Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 229960004778 mipomersen Drugs 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- PSOHUKLWHXJGLR-UHFFFAOYSA-N tert-butyl n-[3-[(6-amino-7h-purin-2-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(N)=C2NC=NC2=N1 PSOHUKLWHXJGLR-UHFFFAOYSA-N 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- WMSUFWLPZLCIHP-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 9h-fluoren-9-ylmethyl carbonate Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)ON1C(=O)CCC1=O WMSUFWLPZLCIHP-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FPQMTWQFFRTHQP-LURJTMIESA-N (2s)-2-(2-aminoethylamino)-5-(diaminomethylideneamino)pentanoic acid Chemical compound NCCN[C@H](C(O)=O)CCCNC(N)=N FPQMTWQFFRTHQP-LURJTMIESA-N 0.000 description 1
- FSEJIWDJVPXHJU-ZETCQYMHSA-N (2s)-6-amino-2-(2-aminoethylamino)hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NCCN FSEJIWDJVPXHJU-ZETCQYMHSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- HSILAFDVJZUQPI-UHFFFAOYSA-N 1,3-benzothiazole-2-sulfonyl chloride Chemical compound C1=CC=C2SC(S(=O)(=O)Cl)=NC2=C1 HSILAFDVJZUQPI-UHFFFAOYSA-N 0.000 description 1
- HDHOUYSWJQKQIV-UHFFFAOYSA-N 1-(10h-phenoxazin-1-yloxy)propan-2-amine Chemical compound O1C2=CC=CC=C2NC2=C1C=CC=C2OCC(N)C HDHOUYSWJQKQIV-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- SBRGQYMCIVBMQJ-UHFFFAOYSA-N 2-[2-(9h-fluoren-9-ylmethoxycarbonylamino)ethylamino]acetic acid Chemical compound C1=CC=C2C(COC(=O)NCCNCC(=O)O)C3=CC=CC=C3C2=C1 SBRGQYMCIVBMQJ-UHFFFAOYSA-N 0.000 description 1
- RZGIMULKYLBTEI-UHFFFAOYSA-N 2-[2-[2-[bis(phenylmethoxycarbonylamino)methylideneamino]ethylamino]-6-(phenylmethoxycarbonylamino)purin-9-yl]acetic acid Chemical compound N1=C(NCCNC(NC(=O)OCC=2C=CC=CC=2)=NC(=O)OCC=2C=CC=CC=2)N=C2N(CC(=O)O)C=NC2=C1NC(=O)OCC1=CC=CC=C1 RZGIMULKYLBTEI-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- BPTVYKQNFQPCGR-UHFFFAOYSA-N 2-[6-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethoxymethyl]-2-oxo-7h-pyrrolo[2,3-d]pyrimidin-3-yl]acetic acid Chemical compound OC(=O)CN1C(=O)N=C2NC(COCCNC(=O)OC(C)(C)C)=CC2=C1 BPTVYKQNFQPCGR-UHFFFAOYSA-N 0.000 description 1
- SMLJSDLXJRGOKW-UHFFFAOYSA-N 2-[9h-fluoren-9-ylmethoxycarbonyl-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]amino]acetic acid Chemical compound C1=CC=C2C(COC(=O)N(CC(O)=O)CCNC(=O)OC(C)(C)C)C3=CC=CC=C3C2=C1 SMLJSDLXJRGOKW-UHFFFAOYSA-N 0.000 description 1
- MYIVSTLKVKWHSX-UHFFFAOYSA-N 2-but-3-ynoxyethyl(diazonio)azanide Chemical compound [N-]=[N+]=NCCOCCC#C MYIVSTLKVKWHSX-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- ZAOXOZAFVMOYAD-UHFFFAOYSA-N 3-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethoxy]propane-1-sulfonic acid Chemical compound CC(C)(C)OC(=O)NCCOCCCS(O)(=O)=O ZAOXOZAFVMOYAD-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- VKKXEIQIGGPMHT-UHFFFAOYSA-N 7h-purine-2,8-diamine Chemical class NC1=NC=C2NC(N)=NC2=N1 VKKXEIQIGGPMHT-UHFFFAOYSA-N 0.000 description 1
- XJGFWWJLMVZSIG-UHFFFAOYSA-N 9-aminoacridine Chemical compound C1=CC=C2C(N)=C(C=CC=C3)C3=NC2=C1 XJGFWWJLMVZSIG-UHFFFAOYSA-N 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- JKOXTYMZFHJAJJ-UHFFFAOYSA-N CC(C)(C)OC(NCCOCCN(CCOCCC#C)C(OC(C)(C)C)=O)=O Chemical compound CC(C)(C)OC(NCCOCCN(CCOCCC#C)C(OC(C)(C)C)=O)=O JKOXTYMZFHJAJJ-UHFFFAOYSA-N 0.000 description 1
- HVVZIPIUJCVNSL-UHFFFAOYSA-N CCOC(C[n]1c(N=C(NC)NC2=O)c2nc1)=O Chemical compound CCOC(C[n]1c(N=C(NC)NC2=O)c2nc1)=O HVVZIPIUJCVNSL-UHFFFAOYSA-N 0.000 description 1
- SGSSKEDGVONRGC-UHFFFAOYSA-N CNC(NC1=O)=Nc2c1nc[nH]2 Chemical compound CNC(NC1=O)=Nc2c1nc[nH]2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical group NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- WSDRAZIPGVLSNP-UHFFFAOYSA-N O.P(=O)(O)(O)O.O.O.P(=O)(O)(O)O Chemical group O.P(=O)(O)(O)O.O.O.P(=O)(O)(O)O WSDRAZIPGVLSNP-UHFFFAOYSA-N 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960001441 aminoacridine Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BCDDBGCLJLAFGA-UHFFFAOYSA-N benzyl (nz)-n-[methylsulfanyloxy(phenylmethoxycarbonylamino)methylidene]carbamate Chemical compound C=1C=CC=CC=1COC(=O)N=C(OSC)NC(=O)OCC1=CC=CC=C1 BCDDBGCLJLAFGA-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000294 dose-dependent toxicity Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- OIKKMWVTZBLVQC-UHFFFAOYSA-N ethyl 2-(4-benzamido-5-iodo-2-oxopyrimidin-1-yl)acetate Chemical compound O=C1N(CC(=O)OCC)C=C(I)C(NC(=O)C=2C=CC=CC=2)=N1 OIKKMWVTZBLVQC-UHFFFAOYSA-N 0.000 description 1
- QXTHXDZIOFAGJI-UHFFFAOYSA-N ethyl 2-[2-(9h-fluoren-9-ylamino)ethylamino]acetate Chemical compound C1=CC=C2C(NCCNCC(=O)OCC)C3=CC=CC=C3C2=C1 QXTHXDZIOFAGJI-UHFFFAOYSA-N 0.000 description 1
- ISIYVAHTDVRTPG-UHFFFAOYSA-N ethyl 2-[2-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propylamino]-6-(phenylmethoxycarbonylamino)purin-9-yl]acetate Chemical compound N1=C(NCCCNC(=O)OC(C)(C)C)N=C2N(CC(=O)OCC)C=NC2=C1NC(=O)OCC1=CC=CC=C1 ISIYVAHTDVRTPG-UHFFFAOYSA-N 0.000 description 1
- AXTZRZLEYYILFQ-UHFFFAOYSA-N ethyl 2-[2-[4-[bis(phenylmethoxycarbonylamino)methylideneamino]butylamino]-6-(phenylmethoxycarbonylamino)purin-9-yl]acetate Chemical compound N1=C(NCCCCNC(NC(=O)OCC=2C=CC=CC=2)=NC(=O)OCC=2C=CC=CC=2)N=C2N(CC(=O)OCC)C=NC2=C1NC(=O)OCC1=CC=CC=C1 AXTZRZLEYYILFQ-UHFFFAOYSA-N 0.000 description 1
- MJHNQAYROLORED-UHFFFAOYSA-N ethyl 2-[6,8-diamino-2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]purin-9-yl]acetate Chemical compound N1=C(CCNC(=O)OC(C)(C)C)N=C2N(CC(=O)OCC)C(N)=NC2=C1N MJHNQAYROLORED-UHFFFAOYSA-N 0.000 description 1
- SYSVPJSOFFHTSB-UHFFFAOYSA-N ethyl 2-[6,8-diamino-2-[4-[(2-methylpropan-2-yl)oxycarbonylamino]butyl]purin-9-yl]acetate Chemical compound N1=C(CCCCNC(=O)OC(C)(C)C)N=C2N(CC(=O)OCC)C(N)=NC2=C1N SYSVPJSOFFHTSB-UHFFFAOYSA-N 0.000 description 1
- HDUAWKRSPOKLFV-UHFFFAOYSA-N ethyl 2-[6-[bis[(2-methylpropan-2-yl)oxycarbonyl]amino]-2-[5-[(2-methylpropan-2-yl)oxycarbonylamino]pentylamino]purin-9-yl]acetate Chemical compound N1=C(NCCCCCNC(=O)OC(C)(C)C)N=C2N(CC(=O)OCC)C=NC2=C1N(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C HDUAWKRSPOKLFV-UHFFFAOYSA-N 0.000 description 1
- RSCSJFUGQHJOJP-UHFFFAOYSA-N ethyl 2-[6-amino-2-[2-[bis(phenylmethoxycarbonylamino)methylideneamino]ethylamino]purin-9-yl]acetate Chemical compound N1=C2N(CC(=O)OCC)C=NC2=C(N)N=C1NCCNC(=NC(=O)OCC=1C=CC=CC=1)NC(=O)OCC1=CC=CC=C1 RSCSJFUGQHJOJP-UHFFFAOYSA-N 0.000 description 1
- CZTBFVIYITWBBB-UHFFFAOYSA-N ethyl 2-[6-amino-2-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propylamino]purin-9-yl]acetate Chemical compound N1=C(NCCCNC(=O)OC(C)(C)C)N=C2N(CC(=O)OCC)C=NC2=C1N CZTBFVIYITWBBB-UHFFFAOYSA-N 0.000 description 1
- XDCAEDJTXHGMFW-UHFFFAOYSA-N ethyl 2-[6-amino-2-[5-[(2-methylpropan-2-yl)oxycarbonylamino]pentylamino]purin-9-yl]acetate Chemical compound N1=C(NCCCCCNC(=O)OC(C)(C)C)N=C2N(CC(=O)OCC)C=NC2=C1N XDCAEDJTXHGMFW-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- SUUIECYTKGRQCI-UHFFFAOYSA-N methyl 2-[2-(9h-fluoren-9-ylmethoxycarbonylamino)ethylamino]acetate Chemical compound C1=CC=C2C(COC(=O)NCCNCC(=O)OC)C3=CC=CC=C3C2=C1 SUUIECYTKGRQCI-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- KUQWAXPYFIYBBY-UHFFFAOYSA-N n-(5-iodo-2-oxo-1h-pyrimidin-6-yl)benzamide Chemical compound IC1=CNC(=O)N=C1NC(=O)C1=CC=CC=C1 KUQWAXPYFIYBBY-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 108010043655 penetratin Proteins 0.000 description 1
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000007903 penetration ability Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- WGCGURPHUSJFKY-UHFFFAOYSA-N tert-butyl 2-[2-(9h-fluoren-9-ylmethoxycarbonylamino)ethylamino]acetate Chemical compound C1=CC=C2C(COC(=O)NCCNCC(=O)OC(C)(C)C)C3=CC=CC=C3C2=C1 WGCGURPHUSJFKY-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- GPTXCAZYUMDUMN-UHFFFAOYSA-N tert-butyl n-(2-hydroxyethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCO GPTXCAZYUMDUMN-UHFFFAOYSA-N 0.000 description 1
- POPGBGYTSRQYLK-UHFFFAOYSA-N tert-butyl n-(2-prop-2-ynoxyethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCOCC#C POPGBGYTSRQYLK-UHFFFAOYSA-N 0.000 description 1
- XDJCYKMWJCYQJM-UHFFFAOYSA-N tert-butyl n-(3-hydroxypropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCO XDJCYKMWJCYQJM-UHFFFAOYSA-N 0.000 description 1
- QIKPEQVGXKJLEY-UHFFFAOYSA-N tert-butyl n-(3-prop-2-ynoxypropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCOCC#C QIKPEQVGXKJLEY-UHFFFAOYSA-N 0.000 description 1
- PDAFIZPRSXHMCO-ZCFIWIBFSA-N tert-butyl n-[(2r)-1-hydroxypropan-2-yl]carbamate Chemical compound OC[C@@H](C)NC(=O)OC(C)(C)C PDAFIZPRSXHMCO-ZCFIWIBFSA-N 0.000 description 1
- VULKFBHOEKTQSF-UHFFFAOYSA-N tert-butyl n-[2-(2-aminoethoxy)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCOCCN VULKFBHOEKTQSF-UHFFFAOYSA-N 0.000 description 1
- NROTZNAWFRRNIS-UHFFFAOYSA-N tert-butyl n-[2-[2-[(6-oxo-3,7-dihydropurin-2-yl)amino]ethoxy]ethyl]carbamate Chemical compound O=C1NC(NCCOCCNC(=O)OC(C)(C)C)=NC2=C1N=CN2 NROTZNAWFRRNIS-UHFFFAOYSA-N 0.000 description 1
- LPHXDOGUEPNTJE-UHFFFAOYSA-N tert-butyl n-[3-(2-aminoethoxy)propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCOCCN LPHXDOGUEPNTJE-UHFFFAOYSA-N 0.000 description 1
- ISGDRUJSNRUSDS-UHFFFAOYSA-N tert-butyl n-[3-(prop-2-ynylamino)propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNCC#C ISGDRUJSNRUSDS-UHFFFAOYSA-N 0.000 description 1
- IVPCGNMZUWWJMC-UHFFFAOYSA-N tert-butyl n-[3-[(6-oxo-3,7-dihydropurin-2-yl)amino]propyl]carbamate Chemical compound O=C1NC(NCCCNC(=O)OC(C)(C)C)=NC2=C1N=CN2 IVPCGNMZUWWJMC-UHFFFAOYSA-N 0.000 description 1
- USFPINLPPFWTJW-UHFFFAOYSA-N tetraphenylphosphonium Chemical compound C1=CC=CC=C1[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 USFPINLPPFWTJW-UHFFFAOYSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108010062760 transportan Proteins 0.000 description 1
- PBKWZFANFUTEPS-CWUSWOHSSA-N transportan Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O)[C@@H](C)CC)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CC=C(O)C=C1 PBKWZFANFUTEPS-CWUSWOHSSA-N 0.000 description 1
- 229940086542 triethylamine Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C07K14/003—Peptide-nucleic acids (PNAs)
Definitions
- the present invention relates to peptide nucleic acid derivatives chemically modified to show good cell penetration and strong affinity for nucleic acid.
- Figure 1 provides HPLC chromatograms before and after purification of Oliqo 17 by reverse phase HPLC.
- Figure 2 provides a MALDI-TOF mass spectrum for a purified batch of Oliqo 17.
- Figure 3 provides graphs of absorbance changes with temperature for Oliqo 17 against complementary or mismatch DNA.
- Figure 4(a) and 4(b) provide confocal microscopy images (at 63x objective) 1, 2, 3 and 24h after HeLa cells were treated with Oliqo 1 and Oliqo 2 at 5 ⁇ M, respectively.
- Figure 5(a) and 5(b) provide confocal microscopy images (at 63x objective) 0.5 and Ih after MCF-7 cells were treated with Oliqo 6 and Oliqo 7 at 2.5 ⁇ M, respectively.
- Figure 6(a) and 6(b) provide confocal microscopy pictures (at 40x objective) 6 or 24h after HeLa cells were treated with Oliqo 1 and Oliqo 6 at l ⁇ M, respectively.
- Figure 7(a) and 7(b) provide confocal microscopy pictures (40x objective) 24h after JAR cells were treated with Oliqo 21 and Oliqo 28 at 2 ⁇ M, respectively.
- Figure 7(c) and 7(d) provide confocal microscopy pictures (at 4Ox objective) 24h after A549 cells were treated with Oliqo 21 and Oliqo 28 at 2 ⁇ M, respectively.
- Figure 7(e) and 7(f) provide confocal microscopy pictures (at 4Ox objective) 12h after HeLa cells were treated with Oliqo 21 and Oliqo 28 at 2 ⁇ M, respectively.
- Figure 7(g) provides confocal microscopy pictures (at 4Ox objective) 24h after HeLa cells were treated with Oliqo 21 at 2 ⁇ M.
- Figure 8(a), 8(b) and 8(c) provide confocal microscopy images (4Ox objective) 24h after HeLa, A549, and JAR cells were treated with 2 ⁇ M Oliqo 22, respectively.
- Figure 9 provides western blotting results for JAR cells treated with 5 ⁇ M or 10 ⁇ M Oliqo 9, 5 ⁇ M or 10 ⁇ M Oliqo 10, cotreatment with the oligomers at 5 ⁇ M or lO ⁇ M each, and blank (no oligomer treatment).
- Figure 10 is the representative structure for the PNA oligomers of this invention.
- Oligonucleotides have been used for diverse biological purposes including antisense inhibition of gene expression, PCR (polymerase chain reaction), diagnostic analysis by gene chips, and so on. Since oligonucleotides interact in a sequence specific manner with nucleic acids such as DNA and RNA, they are quite useful to predictably modulate biological processes involving DNA or RNA within cell. Unlike small molecule drugs, however, oligonucleotides do not readily penetrate mammalian cell membrane, and therefore hardly affect biological processes within cell unless properly modified or formulated to readily penetrate plasma membrane. Proteins as Drug Targets: Proteins mediate diverse cellular functions. It would not be surprising to find that most of currently marketed drugs show therapeutic activity through modulating functions of protein(s).
- non-steroidal anti-inflammatory drug aspirin inhibits enzymes called cyclooxygenases for its anti-inflammatory activity.
- Losartan binds to and antagonize the function of a trans-membrane receptor called angiotensin II receptor for its antihypertensive activity.
- Rosiglitazone selectively activates an intracellular receptor called peroxisome proliferator-activated receptor ⁇ (PPARy) to elicit its antidiabetic activity.
- Etanercept is a fusion protein which binds to a cytokine called tumor necrosis factor- ⁇ (TNF- ⁇ ), and neutralizes the biological activity of TNF- ⁇ for its anti-rheumatic activity.
- Herceptin is a monoclonal antibody to treat breast cancer by selectively binding to erbB2 over-expressed in certain types of breast cancer cells.
- Proteins are encoded by DNA (2-deoxyribose nucleic acid). In response to cellular stimulation, DNA is transcribed to produce pre-mRNA (pre-messenger ribonucleic acid) in the nucleus. The intron portion(s) of pre-mRNA is enzymatically spliced out yielding mRNA (messenger ribonucleic acid), which is then translocated to the cytosolic compartment. In the cytosol, a complex of translational machinery called ribosome binds to mRNA and carries out the protein synthesis as it scans the genetic information encoded along the mRNA. ⁇ Biochemistry MO ⁇ 41, 4503-4510, 2002; Cancer Res.
- AO antisense oligonucleotide
- AO may tightly bind to an mRNA and inhibit the protein synthesis by ribosome along the mRNA in the cytosol. AO needs to be present within cell in order to inhibit the synthesis of its target protein. AO may tightly bind to a pre-mRNA in the nucleus and affect the splicing of the pre-mRNA, producing an mRNA of altered sequence and consequently an altered protein.
- Unnatural Oligonucleotides Oligonucleotides of DNA or RNA are susceptible to degradation by endogenous nucleases, limiting their therapeutic utility. To date, many types of unnatural oligonucleotides have been developed and studied intensively. ⁇ Clin. Exp. Pharmacol. Physiol, vol 33, 533-540, 2006) Some of them show extended metabolic stability compared to DNA and RNA. Provided above are chemical structures for some of representative unnatural oligonucleotides. Such oligonucleotides predictably bind to a complementary nucleic acid as DNA or RNA does.
- Phosphorothioate oligonucleotide is a DNA analog with one of the backbone phosphate oxygen atoms replaced with sulfur atom per monomer. Such a small structural change made PTO comparatively resistant to degradation by nucleases. ⁇ Ann. Rev. Biochem. vol 54, 367-402, 1985) Reflecting the structural similarity of PTO and DNA, they both poorly penetrate cell membrane in most mammalian cell types. For some types of cells abundantly expressing trans porter(s) for DNA, however, DNA and PTO show good cell penetration. Systemically administered PTOs are known to readily distribute to the liver and kidney. ⁇ Nucleic Acids Res.
- PTOs are known to be associated with dose dependent toxicities such as increased coagulation time, complement activation, tubular nephropathy, Kupffer cell activation, and immune stimulation including splenomegaly, lymphoid hyperplasia, mononuclear cell infiltration. ⁇ Clin. Exp. Pharmacol. Physiol, vol 33, 533-540, 2006) Many antisense PTOs have been found to show due clinical activity for diseases with a significant contribution from the liver or kidney.
- ISIS- 301012 is a PTO analog which inhibits the synthesis of apoB- 100, a protein involved in LDL cholesterol transport.
- ISIS- 113715 is an antisense PTO analog inhibiting the synthesis protein tyrosine phosphatase IB (PTPlB), and was found to show therapeutic activity in type II diabetes patients.
- PPOlB synthesis protein tyrosine phosphatase IB
- PMO phosphoroamidite morpholino oligonucleotide
- PNA Peptide nucleic acid
- PNA Like DNA and RNA, PNA also selectively binds to complementary nucleic acid [Nature (London) vol 365, 566-568, 1992] Like PMO, the backbone of PNA is not charged. Thus the binding between PNA and RNA tends to be stronger than that between DNA and RNA. Since PNA is structurally markedly different from DNA, PNA wouldn't be recognized by the hepatic trans porter(s) recognizing DNA, and would show a tissue distribution profile very different from that of DNA or PTO. However, PNA also poorly penetrates mammalian cell membrane. ⁇ Adv. Drug Delivery Rev.
- LNA locked nucleic acid
- Antisense mechanism differs depending on types of AOs. RNAse H recognizes a duplex of mRNA with DNA, RNA, or PTO, and degrades the duplex portion of mRNA. Thus, the antisense activity of PTO is significantly amplified by RNAse H. In the meantime, RNAse H does not recognize a duplex of mRNA with PMO, PNA, or LNA. In other words, PMO, PNA and LNA must rely purely on the steric blocking of mRNA for their antisense activity.
- PTO should therefore show stronger antisense activity than PMO, PNA, and LNA.
- steric block AOs such as PMO, PNA, and LNA, strong affinity for mRNA is desired for antisense activity.
- Antisense Activity of PNA The binding affinity of PNA for mRNA would increase as the length of PNA increases to a certain point. However, the antisense activity of PNA doesn't seem to always increase to the length of PNA. There were cases that the antisense activity of PNA reached the maximum activity at 12 to 13-mer and decreases thereafter. ⁇ Nucleic acids Res. vol 32, 4893-4902, 2004) On the other hand, optimum antisense activity was reached with 15 to 18-mer PNAs against a certain mRNA, reflecting that the structural accessibility of the target binding site of the mRNA would be important.
- PNAs do not readily penetrate cell membrane and tend to show poor antisense activity unless properly transfected. In early years, the antisense activity of PNA was assessed by microinjection (Science vol 258, 1481-85, 1992) or electroporation (Biochemistry vol 40, 7853-7859, 2001). Microinjection and electroporation are invasive and inappropriate to be applied for therapeutic purposes. In order to improve the cell penetration, various strategies have been developed. (Adv. Drug Delivery Rev. vol 55, 267-280, 2003; Curr. Top. Med. Chem.
- PNAs have been effectively delivered into cell by covalent incorporation of cell penetrating peptides ⁇ Neuropeptides vol 38, 316-324, 2004), lipofection following duplex formation with a complementary DNA ⁇ Biochemistry vol 40, 53-64, 2001), lipofection of PNAs with a covalently attached 9-aminoacridine ⁇ Nucleic Acids Res. vol 32, 2695-2706, 2004), lipofection of PNAs with covalently attached phosphonate anions ⁇ Nucleic Acids Res. vol 36, 4424-4432, 2008), and so on.
- PNAs with a Covalently Attached CPP Cell penetrating peptides (CPPs) are polypeptides showing good cell penetration, and have multiple positive charges from arginine or lysine residues. To date many CPPs such as transportan, penetratin, NLS (nuclear localization signal), and Tat have been discovered. CPPs are known to efficiently carry a covalently attached cargo into cell. PNAs with a covalently attached CPP also showed good cell penetration. Although some PNAs with a covalently attached CPP showed antisense IC 50 S around 10OnM ⁇ Neuropeptides vol 38, 316-324, 2004), micromolar antisense IC 50 S are rather prevalent for such PNAs.
- PNAs with a covalently linked CPP are composed of two portions, the hydrophobic PNA domain and the positively charged CPP domain. Such a PNA tends to aggregate and be trapped in endosomes within cell, and would not be available for the antisense inhibition of protein synthesis. ⁇ Curr. Top. Med. Chem. vol 7, 727-737, 2007; Nucleic Acids Res. vol 33, 6837-6849, 2005) Furthermore, such a covalently attached CPP hardly increases the binding affinity of PNA for mRNA.
- PNAs with a Chiral Backbone There have been attempts to introduce a chiral substituent on the PNA backbone of 2-aminoethyl-glycine (Aeg).
- the aqueous solubility of PNA was significantly improved by incorporating PNA monomer(s) with a backbone of 2-aminoethyl-lysine in place of Aeg. ⁇ Angew. Chem. Int. Ed. Engl, vol 35, 1939-1941, 1996)
- a backbone of 2-aminoethyl-lysine in place of Aeg. ⁇ Angew. Chem. Int. Ed. Engl, vol 35, 1939-1941, 1996)
- the binding affinity of PNA for DNA and RNA was significantly improved.
- a 10-mer PNA with all of the backbone of L-(2-amino-2- methyl)ethyl-glycine in place of 2-aminoethyl-glycine showed an increase of 19 0 C and 10 0 C in T m against complementary DNA and RNA, respectively. Such an increase doesn't seem to be proportional to the number of substitution with L-(2-amino-2-methyl)ethyl-glycine, though. [J. Am. Chem. Soc. vol 128, 10258-10267, 2006)
- GPNA The cell penetration of PNA was reported to be markedly improved by incorporating PNA monomers with a backbone of 2-aminoethyl-arginine in place of Aeg. [J. Am. Chem. Soc. vol 125, 6878-6879, 2003) Such PNAs have been termed 'GPNA' since they have guanidinium moiety on the backbone. GPNAs with the backbone of 2-aminoethyl-D-arginine were reported to have stronger affinity for DNA and RNA than the corresponding GPNAs with that of 2-aminoethyl-L-arginine. [Chem. Commun.
- PNAs with Modified Nucleobase Like cases with DNA, nucleobase modifications have been pursued to improve PNA's affinity for nucleic acids. PNAs with adenine replaced with 2,6-diaminopurine were evaluated for their affinity for complementary DNA or RNA. Substitution with 2,6- diaminopurine was found to elicit an increase of 2.5 ⁇ 6 0 C in T m per replacement. ⁇ Nucleic Acids Res. vol 25, 4639-4643, 1997)
- PNAs with cytosine replaced with 9-(2-aminoethoxy)phenoxazine were evaluated for their affinity for complementary DNA or RNA.
- a single substitution with 9-(2-aminoethoxy)phenoxazine elicited an increase of 10.7 ⁇ 23.7°C in T m , although such an increase was markedly dependent on the nucleotide sequence.
- Nucleobase 9-(2-aminopropoxy)phenoxazine also induced a large increase in T m .
- PNA monomer with either 9-(2-aminoethoxy)-phenoxazine or 9-(2- aminoethoxy)phenoxazine as a cytosine replacement has been termed 1 G- clamp'.
- cytosine replaced with either 6- ⁇ 2-(2-aminoethoxy)phenyl ⁇ - pyrrolocytosine or 6- ⁇ 2,6-di(2-aminoethoxy)phenyl ⁇ pyrrolocytosine were evaluated for their affinity for complementary DNA or RNA.
- PNA By tightly binding to a microRNA, PNA can inhibit the regulatory function of the microRNA, leading to an increase in the expression level of the protein(s) directly regulated by the microRNA.
- RNA vol 14, 336-346, 2008 By tightly binding to a ribonucleoprotein such as telomerase, PNA can modulate the cellular function of the ribonucleoprotein.
- telomerase By tightly binding to a certain portion of a gene in the nucleus, PNA can modulate the transcription level of the gene.
- the present invention provides a novel class of PNA oligomers represented by Formula I, or a pharmaceutically acceptable salt thereof:
- n is an integer equal to or larger than 5;
- Si, S 2 , ..., S n- I, S n , Ti, T 2 , ..., T n- I, and T n independently represent hydrido, deuterido, substituted or non-substituted alkyl, or substituted or non-substituted aryl radical;
- X and Y independently represent hydrido, deuterido, hydroxy, substituted or non-substituted alkyloxy, substituted or non-substituted aryloxy, substituted or non-substituted amino, substituted or non-substituted alkyl, substituted or non-substituted acyl, substituted or non-substituted sulfonyl, or substituted or non-substituted aryl radical;
- Z represents hydrido, deuterido, hydroxy, substituted or non- substituted alkyloxy, substitute
- a PNA oligomer of Formula I shows improved binding affinity for nucleic acid and cell penetration compared to its corresponding 'unmodified' PNA oligomer.
- PNA oligomers of this invention are useful to sequence specifically inhibit or modulate cellular and physiological functions mediated by nucleic acids or physiologically active molecules having a nucleic acid domain such as ribonucleoproteins. Also PNA oligomers of this invention are useful for diagnostic purposes due to their sequence specific binding capability for nucleic acids.
- the present invention provides a novel class of PNA oligomers represented by Formula I, or a pharmaceutically acceptable salt thereof:
- n is an integer equal to or larger than 5;
- Si, S 2 , ..., S n- I, S n , Ti, T 2 , ..., T n- I, and T n independently represent hydrido, deuterido, substituted or non-substituted alkyl, or substituted or non-substituted aryl radical;
- X and Y independently represent hydrido, deuterido, hydroxy, substituted or non-substituted alkyloxy, substituted or non-substituted aryloxy, substituted or non-substituted amino, substituted or non-substituted alkyl, substituted or non-substituted acyl, substituted or non-substituted sulfonyl, or substituted or non-substituted aryl radical;
- Z represents hydrido, deuterido, hydroxy, substituted or non- substituted alkyloxy, substitute
- a PNA oligomer of this invention shows improved cell penetration and binding to nucleic acid compared to its corresponding 'unmodified' PNA oligomer.
- 'unmodified' PNA oligomer refers to a PNA oligomer of Formula I, wherein Si, S 2 , ..., S n- I, S n , Ti, T 2 , ..., T n- I, and T n are hydrido radical; and Bi, B 2 , ..., B n- i, and B n are independently selected from natural nucleobases comprising adenine, thymine, guanine, and cytosine.
- a PNA oligomer of this invention readily penetrates mammalian cell membrane, and can affect or alter cellular functions by sequence specifically binding to a nucleic acid or a nucleoprotein within cell.
- a PNA oligomer of Formula I can potently inhibit ribosomal protein synthesis by tightly binding to mRNA.
- a PNA oligomer of the present invention can tightly bind to a pre-mRNA and alter the splicing of the pre- mRNA to mRNA. Further, a PNA oligomer of the present invention can bind tightly to a microRNA, and inhibit mRNA degradation induced by the microRNA.
- a PNA oligomer of Formula I can predictably bind to the nucleic acid domain of a ribonucleoprotein, for example telomerase, and modulate its physiological function(s).
- a PNA oligomer of the present invention can bind to a gene and modulate the transcription of the gene.
- a PNA oligomer of Formula I can bind to a viral gene or its transcript, and inhibit the proliferation of the virus.
- a PNA oligomer of this invention can affect cellular functions other than those described above by sequence specifically binding to a nucleic acid or a nucleoprotein within mammalian cell.
- a PNA oligomer of the present invention can tightly bind to a bacterial mRNA, nucleic acid, or gene, and inhibit bacterial proliferation or alter bacterial biosynthesis profiles.
- a PNA oligomer of this invention is highly sensitive to a base mismatch in binding to its complementary DNA counterpart, and would be appropriate for detecting single nucleotide polymorphism (SNP) with high fidelity.
- SNP single nucleotide polymorphism
- a PNA oligomer of Formula I may be useful to probe or locate a nucleic acid bearing molecule such as telomere within cell if properly tagged with a chromophore, for example, fluorophore.
- PNA oligomers of this invention may be useful for a variety of diagnostic or analytical purposes other than those detailed above.
- a PNA oligomer of the present invention possesses good aqueous solubility compared to the corresponding 'unmodified' PNA oligomer, and can be used as dissolved in water, saline, or a buffer solution.
- a PNA oligomer of Formula I can be formulated with a cationic lipid such as lipofectamine.
- a PNA oligomer of this invention may be duplexed with a complementary DNA and the resulting duplex can be formulated with a cationic lipid.
- a PNA oligomer of this invention may be formulated in a variety of dosage forms including but not limited to injectable formulation, nasal spray, tablet, granules, hard capsule, soft capsule, liposomal formulation, oral suspension, transdemal formulation, and so on.
- a PNA oligomer of the present invention can be administered to a subject at therapeutically effective doses, which would vary depending on indication, administration route, dosing schedule, situations of subject, and so on.
- a PNA oligomer of the present invention can be administered to a subject by a variety of routes including but not limited to intravenous injection, subcutaneous injection, intraperitoneal injection, nasal inhalation, oral administration, transdermal application, and so on.
- a PNA oligomer of Formula I can be administered to a subject in combination with a pharmaceutically acceptable adjuvant including but not limited to citric acid, hydrochloric acid, tartaric acid, stearic acid, polyethyleneglycol, polypropyleneglycol, ethanol, sodium bicarbonate, distilled water, hyaluronic acid, cationic lipid such as lipofectamine, starch, gelatin, talc, ascorbic acid, olive oil, palm oil, methylcelluose, titanium oxide, sodium carboxymethylcellulose, sweetener, preservative, and so on.
- a pharmaceutically acceptable adjuvant including but not limited to citric acid, hydrochloric acid, tartaric acid, stearic acid, polyethyleneglycol
- a PNA oligomer of the present invention may be used as neutralized with an equivalent amount of a pharmaceutically acceptable acid or base including but not limited to sodium hydroxide, potassium hydroxide, hydrochloric acid, methanesulfonic acid, citric acid, and so on.
- a pharmaceutically acceptable acid or base including but not limited to sodium hydroxide, potassium hydroxide, hydrochloric acid, methanesulfonic acid, citric acid, and so on.
- Preferred PNA oligomers encompass PNA oligomers of Formula I, or a pharmaceutically acceptable salt thereof: wherein, n is an integer equal to or larger than 5 but smaller than or equal to 30; Si, S 2 , ..., S n- I, S n , T 1 , T 2 , ..., T n -I, and T n are hydrido radical; X and Y are independently selected from hydrido, substituted or non- substituted alkyl, substituted or non-substituted acyl, substituted or non- substituted sulfonyl, and substituted or non-substituted aryl radical; Z represents hydrido, hydroxy, substituted or nonsubstituted alkyloxy, substituted or non-substituted amino, substituted or non-substituted alkyl, or substituted or non-substituted aryl radical; Bi, B 2 , ..., B n -I,
- Formula Il Formula III Formula IV wherein, R 1 , R 2 , R3, R 4 , Rs and R 6 are independently selected from substituted or non-substituted alkyl, hydrido, hydroxy, and substituted or non- substituted alkyloxy radical; and, L 1 , L 2 and L 3 are a covalent linker represented by Formula V connecting a basic amino group to the moiety responsible for nucleobase pairing properties: For m u , a V
- Qi and Q m are substituted or non-substituted methylene (-CH 2 -) radical, and Q m is directly linked to the basic amino group;
- Q 2 , Q 3 , ..., and Q m- i are independently selected from substituted or non-substituted methylene, oxygen (-O-), sulfur (-S-), and substituted or non-substituted amino radical [-N(H)-, or -N(substituent)-]; and, m is an integer equal to or larger than 2 but smaller than or equal to 15.
- PNA oligomers of particular interest comprise PNA oligomers of Formula I, or a pharmaceutically acceptable salt thereof: wherein, n is an integer equal to or larger than 8 but smaller than or equal to 25; Si, S 2 , ..., S n -I, S n , Ti, T 2 , ..., T n-I , and T n are hydrido radical; X and Y are independently selected from hydrido, substituted or non- substituted alkyl, and substituted or non-substituted acyl radical; Z represents hydroxy, or substituted or non-substituted amino radical; Bi, B 2 , ..., B n-I , and B n are independently selected from natural nucleobases including adenine, thymine, guanine, cytosine and uracil, and unnatural nucleobases; at least two of Bi, B 2 , ..., B n- i, and B n are independently selected from
- PNA oligomers of high interest comprise PNA oligomers of Formula I, or a pharmaceutically acceptable salt thereof: wherein, n is an integer equal to or larger than 10 but smaller than or equal to 25; Si, S 2 , ..., S n- I, S n , Ti, T 2 , ..., T n - I , and T n are hydrido radical; X and Y are independently selected from hydrido, and substituted or non-substituted acyl radical; Z represents hydroxy, alkyloxy, or substituted or non-substituted amino radical; and, Bi, B 2 , ..., B n- I, and B n are independently selected from natural nucleobases including adenine, thymine, guanine, cytosine and uracil, and unnatural nucleobases; at least three of Bi, B 2 , ..., B n - I , and B n are independently selected from unnatural nucle
- PNA oligomers of higher interest encompass PNA oligomers of Formula I, or a pharmaceutically acceptable salt thereof: wherein, n is an integer equal to or larger than 10 but smaller than or equal to 20; S 1 , S 2 , ..., S n -I, S n , T 1 , T 2 , ..., T n-1 , and T n are hydrido radical; X and Y are independently selected from hydrido, and substituted or non-substituted acyl radical; Z represents hydroxy, or substituted or non-substituted amino radical; Bi, B 2 , ..., B n-I , and B n is independently selected from natural nucleobases including adenine, thymine, guanine, cytosine and uracil, and unnatural nucleobases; at least three of Bi, B 2 , ..., B n- i, and B n are independently selected from unnatural nucleobases represented
- PNA oligomers of highest interest comprise PNA oligomers of Formula I, or a pharmaceutically acceptable salt thereof: wherein, n is an integer equal to or larger than 10 but smaller than or equal to 20; S 1 , S 2 , ..., S n- I, S n , Ti, T 2 , ..., T n -I, and T n are hydrido radical; X and Y are independently selected from hydrido, and substituted or non-substituted acyl radical; Z represents hydroxy, or substituted or non-substituted amino radical; Bi, B 2 , ..., B n-I , and B n are independently selected from adenine, thymine, guanine, cytosine, and unnatural nucleobases; at least three of Bi, B 2 , ..., B n -i, and B n are independently selected from unnatural nucleobases represented by Formula II, Formula III, or Formula IV, Ri, R
- PNA oligomers of strong interest comprise PNA oligomers of Formula I, or a pharmaceutically acceptable salt thereof: wherein, n is an integer equal to or larger than 8 but smaller than or equal to 20; Si, S 2 , ..., S n- I, S n , Ti, T 2 , ..., T n- I, and T n are hydrido radical; X is hydrido radical; Y represents hydrido, or substituted or non-substituted acyl radical; Z represents hydroxy, or substituted or non-substituted amino radical; Bi, B 2 , ..., B n-I , and B n are independently selected from adenine, thymine, guanine, cytosine, and unnatural nucleobases; at least three of Bi, B 2 , ..., B n-I , and B n are independently selected from unnatural nucleobases represented by Formula II, Formula III, or Formula IV; Ri,
- NMR spectra were recorded on a Varian Mercury 300MHz, Bruker Avance 400MHz, or Varian Inova 500MHz NMR spectrometer. Either a Bruker Daltonics Ultraflex MALDI-TOF or an Agilent LC/MS Ion Trap System was employed for determination of molecular weight. PNA oligomers were analyzed and purified by Ci 8 -reverse phase HPLC either on a Hewlett Packard 1050 HPLC or a Shimazu LC-6AD HPLC. Unless noted otherwise, silica gel was used for chromatographic separation of small molecules prepared in this invention. Melting point is reported as uncorrected.
- Unnatural nucleobase derivatives used for the synthesis of PNA monomers of this invention were prepared according to one of the methods (Methods A, B, and C) provided below or with minor modification(s) thereof, unless detailed otherwise in actual synthetic examples.
- Method A 6-alkyl-pyrollocytosine derivatives were synthesized as properly protected according to Scheme 1 or with minor variation(s) thereof. Such 6- alkyl-pyrollocytosine derivatives were used to synthesize PNA monomers containing a nucleobase represented by Formula Il as a cytosine equivalent.
- First compound a was deprotonated with NaH and then alkylated with ethylbromoacetate to obtain compound b.
- Method B 2,6-diaminopurine derivatives were synthesized as properly protected according to Scheme 2 or with minor variation(s) thereof. Such 2,6-diamino-purine derivatives were used to synthesize PNA monomers containing a nucleobase represented by Formula III as an adenine equivalent.
- First 2-haloadenine was reacted with a diamine at high temperature to obtain compound d, which was then reacted with BoC 2 O to give compound e.
- Compound e was deprotonated with NaH, and alkylated with ethylbromoacetate to obtain compound f.
- the aromatic amino group of compound f was protected with either Cbz or Boc group to yield compound g
- N-alkylated guanine derivatives were synthesized as properly protected according to Scheme 3 or with minor variations thereof. Such guanine derivatives were used to synthesize PNA monomers containing a nucleobase represented by Formula IV as a guanine equivalent.
- PNA oligomers Two types were synthesized according to either Method D or Method E to prepare PNA oligomers of Formula I.
- PNA oligomers were prepared by Panagene, Inc. (www.panagene.com, Daejon, South Korea) using PNA monomers of type o of Scheme 4 upon request of CTI Bio.
- PNA monomers of type q of Scheme 5 were used in- house for the synthesis of PNA oligomers according to the method described in the prior art or with minor modification(s) thereof. (USP 6,133,444)
- Method D PNA monomers with a modified nucleobase were prepared according to Scheme 4 or with minor variation(s) thereof as properly protected for the PNA oligomer synthesis method described in the literature. ⁇ Org. Lett, vol 9, 3291-3293, 2006) In Scheme 4, compound k may correspond to compound c of Scheme 1, compound g of Scheme 2, or compound j of Scheme 3, however, may not be necessarily limited to one of those ester compounds.
- Method E PNA monomers with a modified nucleobase were prepared according to Scheme 5 or with minor variation(s) thereof as properly protected for the PNA oligomer synthesis method provided in the prior art.
- compound k may correspond to compound c of Scheme 1, compound g of Scheme 2, or compound j of Scheme 3, however, may not be necessarily limited to one of those ester compounds.
- First acid I was coupled with ethyl N-[2- ⁇ N-(9H-fluoren-9- yl)amino ⁇ ethyl]-glycinate to obtain compound p by an EDCI coupling reaction. Then compound p was mildly hydrolyzed with LiOH to obtain PNA monomer q with a modified nucleobase.
- Example 2 Preparation of ethyl ⁇ (N-benzoyl)-5-iodocytosine-l-yl ⁇ acetate (2). To a stirred solution of 8.3g of N-benzoyl-5-iodocytosine dissolved in 60ml DMF, was added at O 0 C 1.06g of 55% NaH in mineral oil, and the solution was stirred at RT for 2h. After 2.7ml ethyl bromoacetate was added to the reaction mixture, the reaction solution was stirred for another 24h at RT, which was followed by removal of the solvent under reduced pressure. The resulting residue was dissolved and the insoluble material was filtered off.
- Example 8 Preparation of 2- ⁇ (t-butoxycarbonyl)amino ⁇ -l-(2-propynyl-l- oxy) ⁇ -(R)-propane (8).
- the organic layer was concentrated and dissolved in 80ml THF and 80ml water, to which was added 8.4g of BoC 2 O dissolved in 50ml THF.
- the reaction mixture was stirred at RT for 16h, which was followed by removal of THF in vacuo and extraction with EA.
- the organic layer was washed in series with 0.5M aq citric acid, water, and brine.
- the organic layer was dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography (hexane -> 1:4 EA/hexane) to obtain 2.45g of compd 9 as a pale yellow oil.
- Example 10 Preparation of ethyl 2-[6- ⁇ 3-(t-butoxycarbonylamino)propyl-l- oxy ⁇ -methyl-2-oxo-2H-pyrrolo[2,3-d]pyrimidin-3(7H)-yl]acetate (10).
- Example 11 Preparation of 2-[6- ⁇ 3-(t-butoxycarbonylamino)propyl-l- oxy ⁇ methyl-2-oxo-2H-pyrrolo-[2,3-d]pyrimidin-3(7H)-yl]acetic acid (11).
- Example 12 Preparation of ethyl N-[2- ⁇ (benzo[d]thiazole-2-sulfonyl)amino ⁇ - ethyl]-N-[2-[6- ⁇ 3-(t-butoxycarbonylamino)propyl-l-oxy ⁇ methyl-2-oxo-2H- pyrrolo-[2,3-d]pyrimidin-3(7H)-yl]acetyl]glycinate (12).
- Example 13 Preparation of N-[2- ⁇ (benzo[d]thiazole-2-sulfonyl)amino ⁇ ethyl]- N-[2-[6- ⁇ 3-(t-butoxycarbonylamino)propyl-l-oxy ⁇ methyl-2-oxo-2H-pyrrolo- [2,3-d]-pyrimidin-3(7H)-yl]acetyl]glycine (13).
- Example 14 Preparation of l- ⁇ (benzo[d]thiazole-2-sulfonyl) ⁇ -2-oxo-4-[6- ⁇ 3- (t-butoxycarbonylamino)propyl-l-oxy ⁇ methyl-2-oxo-2H-pyrrolo[2,3- d]pyrimidin-3(7H) -yl]acetyl]piperazine (14).
- pyrollocytosine derivatives 15 ⁇ 20 were prepared by similarly following the procedure described in Example 10. Spectral and physical data for compds 15 ⁇ 20 are provided in the table below.
- Examples 15 ⁇ 20 Analytical data for pyrollocytosine derivatives 15 ⁇ 20.
- modified cytosine PNA monomers 21 ⁇ 24 were prepared by similarly following the procedures described in Examples 11 ⁇ 14. Spectral and physical data for compds 21 ⁇ 24 are provided in the table below. Examples 21 ⁇ 24: Analytical data for cytosine PNA monomers 21 ⁇ 24.
- Example 25 Preparation of 2- ⁇ 3-(t-butoxycarbonylamino)propyl ⁇ amino- adenine (25).
- 2,6- diaminopurine derivatives 26 ⁇ 30 were prepared by similarly following the procedure described in Example 25. Spectral and physical data for compounds 26 ⁇ 30 are provided in the table below.
- Examples 26 ⁇ 30 Analytical data for 2,6-diaminopurine derivatives 26 ⁇ 30.
- Example 32 Preparation of ethyl 2-[6-amino-2- ⁇ 3-(t-butoxycarbonylamino)- propyl ⁇ amino-9H-purin-9-yl]acetate (32).
- Example 33 Preparation of ethyl 2-[6-(benzyloxycarbonyl)amino-2- ⁇ 3-(t- butoxy-carbonylamino)propyl ⁇ amino-9H-purin-9-yl]acetate (33).
- Example 34 Preparation of ethyl N-[2- ⁇ 2-(benzo[d]thiazole)sulfonyl ⁇ amino- ethyl]-N-[2-[6-(benzyloxycarbonyl)amino-2- ⁇ 3-(t-butoxycarbonylamino)- propyl ⁇ amino-9H-purin-9-yl]acetyl]glycinate (34).
- Example 35 Preparation of l-(benzo[d]thiazole-2-sulfonyl)-2-oxo-4-[[6- (benzyl-oxycarbonyl)amino-2- ⁇ 3-(t-butoxycarbonylamino)propylamino ⁇ -9H- purin-9-yl]-acetyl]piperazine (35).
- modified adenine PNA monomers 36 ⁇ 40 were prepared by similarly following the procedures described in Examples 32 ⁇ 35. Spectral and physical data for compds 36 ⁇ 40 are provided in the table below.
- Examples 36 ⁇ 40 Analytical data for adenine PNA monomers 36 ⁇ 40.
- Example 41 Preparation of ethyl 2-[2-[2- ⁇ 2-(t-butoxycarbonyamino)-2- methyl ⁇ ethyl]amino-6-oxo-6,9-dihydro-lH-purin-2-yl]acetate (41).
- Example 44 Preparation of 2-[2-[3-(t-butoxycarbonylamino)propyloxy ⁇ - ethyl]]-amino-lH-purin-6(9H)-one (44).
- Example 45 Preparation of 2- ⁇ 3-(t-butoxycarbonylamino)propyl ⁇ amino-lH- purin-6(9H)-one (45).
- Guanine derivatives 46 ⁇ 47 were prepared using a proper diamine by similarly following the procedure described in Example 45. Spectral and physical data for compds 46 ⁇ 47 are provided in the table below.
- Compds 43 ⁇ 46 were transformed into compds 48 ⁇ 51 by similarly following the procedure described in Example 32.
- Spectral and physical data for compounds 48 ⁇ 51 are provided in the table below.
- modified guanine PNA monomers 52 ⁇ 54 were prepared by similarly following the procedures described in Examples 34 ⁇ 35. Spectral and physical data for compds 52 ⁇ 54 are provided in the table below.
- Examples 52 ⁇ 54 Analytical data for guanine PNA monomers 52 ⁇ 54.
- Example 55 Preparation of ethyl 2-[6-amino-2- ⁇ 2-(t-butoxycarbonyl- amino)ethyl ⁇ -amino-9H-purin-9-yl]acetate (55).
- Compd 55 was prepared from compd 26 by similarly following the procedure for Example 32. Pale yellow solid.
- Example 56 Preparation of ethyl 2-[6-amino-2-[2- ⁇ 2,3-bis(benzyloxy- carbonyl)guanidino ⁇ ethyl]amino-9H-purin-9-yl]acetate (56).
- Example 57 Preparation of ethyl 2-[6-(benzyloxycarbonylamino)-2-[2- ⁇ 2,3- bis-CbenzyloxycarbonyOguanidinoJethyllamino-gH-purin-g-yllacetate (57).
- compd 56 4.54g of compd 56 and 8.22g of N-(benzyloxycarbonyl)-N'-methyl- imidazolium triflate were dissolved in 90ml DMF, and stirred for 29h at RT. The solvent was removed under reduced pressure, and the resulting residue was purified by column chromatography (1:3 hexane/EA) to afford 3.06g of compd 57 as a white foam/solid.
- Example 58 Preparation of ethyl 2-[6-amino-2- ⁇ 4-(t-butoxycarbonyl- amino)butyl ⁇ -amino-9H-purin-9-yl]acetate (58).
- Compd 58 was prepared from compd 27 as a reddish yellow foam/solid by similarly following the procedure described in Example 32.
- 1 H NMR (500MHz; DMSO d6 ) ⁇ 7.67 (s, IH), 6.79 (t, IH), 6.69 (s, 2H), 6.30 (m, IH), 4.85 (s, 2H), 4.15 (q, 2H), 3.22-3.17 (m, 2H), 2.93-2.89 (m, 2H), 1.45 (m, 2H), 1.40-1.36 (m, HH), 1.21 (t, 3H).
- Example 59 Preparation of ethyl 2-[6-(benzyloxycarbonylamino)-2-[4- ⁇ 2,3- bis-(benzyloxycarbonyl)guanidino ⁇ butyl]amino-9H-purin-9-yl]acetate (59).
- Compd 59 was prepared from compd 58 as a pale yellow foam/solid by similarly following the procedures described in Examples 56 ⁇ 57.
- 1 H NMR (500MHz; DMSO d6 ) ⁇ 11.49 (s, IH), 10.12 (s, IH), 8.28 (t, IH), 7.91 (s, IH), 7.45-7.31 (m, 5H), 6.95 (t, IH), 5.17 (s, 2H), 4.93 (s, 2H), 4.16 (q, 2H), 3.28 (m, 4H), 1.51 (m, 4H), 1.46 (s, 9H), 1.38 (s, 9H), 1.21 (t, 3H).
- Example 60 Preparation of ethyl 2-[6-amino-2- ⁇ 5-(t-butoxycarbonylamino)- pentyl ⁇ amino-9H-purin-9-yl]acetate (60).
- Compd 60 was prepared from compd 28 as a reddish yellow foam/solid by similarly following the procedure described in Example 32.
- 1 H NMR (500MHz; DMSO d6 ) ⁇ 7.67 (s, IH), 6.78 (t, IH), 6.69 (s, 2H), 6.28 (m, IH), 4.85 (s, 2H), 4.15 (q, 2H), 3.18 (q, 2H), 2.89 (q, 2H), 1.47 (m, 2H), 1.40-1.34 (m, HH), 1.25 (m, 2H), 1.21 (t, 3H).
- Example 61 Preparation of ethyl 2-[6- ⁇ di-(t-butoxycarbonyl) ⁇ amino-2-[5- ⁇ (t- butoxycarbonyl)amino ⁇ pentyl]amino-9H-purin-9-yl]acetate (61).
- Example 62 Preparation of ethyl 2-[2-[2- ⁇ 2,3-bis-(benzyloxycarbonyl)- guanidino ⁇ ethyl]amino-6-oxo-6,9-dihydro-lH-purin-2-yl]acetate (62).
- Compd 50 was converted to compd 62 as a white solid by similarly following the procedure described in Example 57.
- 1 H NMR (500MHz; DMSOd 6 ) ⁇ 11.59 (s, IH), 10.68 (s, IH), 8.50 (t, IH), 7.68 (s, IH), 7.42-7.29 (m, 10H), 6.58 (m, IH), 5.13 (s, 2H), 5.02 (s, 2H), 4.86 (s, 2H), 4.12 (q, 2H), 3.50 (m, 2H), 3.46 (m, 2H), 1.18 (t, 3H).
- Example 63 Preparation of 2-[6-(benzyloxycarbonylamino)-2-[2- ⁇ 2,3-bis- (benzyloxycarbonyl)guanidino ⁇ ethyl]amino-9H-purin-9-yl]acetic acid (63).
- Example 64 Preparation of t-butyl N-[2- ⁇ (9H-fluoren-9-yl)methoxycarbonyl- amino ⁇ ethyl)]-N-[2- ⁇ 6-(benzyloxycarbonylamino)-2-[2- ⁇ 2,3-bis-(benzyloxy- carbonyl)-guanidino ⁇ ethyl]amino-9H-purin-9-yl ⁇ acetyl]glycinate (64).
- Example 65 Preparation of N-[2- ⁇ (9H-fluoren-9-yl)methoxycarbonylamino ⁇ - ethyl)]-N-[2- ⁇ 6-(benzyloxycarbonylamino)-2-[2- ⁇ 2,3-bis(benzyloxycarbonyl)- guanidino ⁇ ethyl]amino-9H-purin-9-yl ⁇ acetyl]glycine (65).
- Example 66 Preparation of N-[2- ⁇ (9H-fluoren-9-yl)methoxycarbonylamino ⁇ - ethyl)]-N-[2- ⁇ 6-(benzyloxycarbonylamino)-2-[4- ⁇ 2,3-bis(benzyloxycarbonyl)- guanidino ⁇ -butyl]amino-9H-purin-9-yl ⁇ acetyl]glycine (66).
- Compd 59 was converted to compd 66 as a white foam/solid by similarly following the procedures described in Examples 63 ⁇ 65.
- MS/ESI (m + 1) 978
- Example 67 Preparation of N-[2- ⁇ (9H-fluoren-9-yl)methoxycarbonylamino ⁇ - ethyl)]-N-[2-[6-[2- ⁇ 2,3-bis(benzyloxycarbonyl)guanidino ⁇ ethoxy]methyl-2-oxo- 2H-pyrrolo[2,3-d]pyrimidin-3(7H)-yl]acetyl]glycine (67).
- Compd 18 was converted to compd 67 as a pale yellow solid by similarly following the procedures described in Examples 63 ⁇ 65.
- Example 68 Preparation of N-[2- ⁇ (9H-fluoren-9-yl)methoxycarbonylamino ⁇ - ethyl)]-N- ⁇ 2-[2- ⁇ 2,3-bis-(benzyloxycarbonyl)guanidino ⁇ ethyl]amino-6-oxo-6,9- dihydro-lH-purin-2-yl]acetyl ⁇ glycine (68).
- Compd 62 was converted to compd 68 as a white foam/solid by following the procedures described in Examples 63 ⁇ 65.
- Example 70 Preparation of methyl N-[2- ⁇ (9H-fluoren-9-yl)methoxycarbonyl- amino ⁇ ethyl)]-N- ⁇ 2-[6- ⁇ 2-(t-butoxycarbonylamino)ethoxy ⁇ methyl-2-oxo-2H- pyrrolo-[2,3-d]pyrimidin-3(7H)-yl]acetyl ⁇ glycinate (70).
- Example 71 Preparation of N-[2- ⁇ (9H-fluoren-9-yl)methoxycarbonylamino ⁇ - ethyl)]-N- ⁇ 2-[6- ⁇ 2-(t-butoxycarbonylamino)ethoxy ⁇ methyl-2-oxo-2H-pyrrolo- [2,3-d]pyrimidin-3(7H)-yl]acetyl ⁇ glycine (71).
- Example 72 Preparation of N-[2- ⁇ (9H-fluoren-9-yl)methoxycarbonylamino ⁇ - ethyl)]-N- ⁇ 2-[5- ⁇ (t-butoxycarbonyl)amino ⁇ pentyl]amino-6-oxo-6,9-dihydro-lH- purin-2-yl]acetyl ⁇ glycine (72).
- Compd 51 was converted to compd 72 as a white foam/solid by similarly following the procedures described in Examples 69 ⁇ 71.
- Example 73 Preparation of N-[2- ⁇ (9H-fluoren-9-yl)methoxycarbonylamino ⁇ - ethyl)]-N-[2-[6- ⁇ bis(t-butoxycarbonyl)amino ⁇ -2- ⁇ 5-(t-butoxycarbonylamino)- pentyl ⁇ amino-9H-purin-9-yl]acetyl]glycine (73).
- Compd 61 was converted to compd 73 as a white foam/solid by similarly following the procedures described in Examples 69 ⁇ 71.
- PNA Oligomers o which were synthesized according to Scheme 4, were sent to Panagene, Inc (www.panagene.com, Daejon, South Korea) to prepare PNA oligomers of Formula I by Panagene according to the method described in the literature or with minor modification(s) thereof. ⁇ Org. Lett, vol 9, 3291-3293, 2006) PNA oligomers were received from Panagene as characterized by MALDI-TOF and analyzed by Cis-reverse phase HPLC. PNA oligomers received from Panagene were used without further purification.
- PNA monomers q of Scheme 5 were used to synthesize PNA oligomers of Formula I according to the method disclosed in the prior art or with minor modification(s) thereof.
- USP 6,133,444 Those PNA oligomers were purified by C 18 -reverse phase HPLC (aq acetonitrile with 0.1% TFA) and characterized by MALDI-TOF.
- Figure 1 provides HPLC chromatograms before and after purification of Oliqo 17 by reverse phase HPLC.
- Figure 2 provides a MALDI-TOF mass spectrum for a purified batch of Oliqo 17.
- Figures 1 and 2 are provided for illustrative purposes only and should not be interpreted as a restriction to this invention.
- PNA oligomers synthesized for this invention are provided in Table 1 along with their molecular weight data by MALDI-TOF.
- A, T, G, and C refer to unmodified nucleobase adenine, thymine, guanine, and cytosine, respectively.
- Modified nucleobases C(mXn), C(mXn g ), A(mXn), A(m), A(mg), and G(m) are as defined below Table 1 along with Lys, Fam, L(I), and L(2).
- PNA oligomers of this invention were evaluated for their binding affinity for DNA by measuring T m values as follows.
- Figure 3 provides graphs of absorbance changes with temperature for Oliqo 17 against complementary or mismatch DNA. For sequences of the mismatch DNAs against Oliqo 17, refer to Table 2. In Figure 3, there is a transition temperature in each curve, which was read out as the T m value for the curve.
- T m values are provided in Table 2 for PNA oligomers of this invention. These T m values are presented for illustrative purposes only and should not be interpreted as a restriction to this invention.
- cytosine with an unnatural nucleobase pyrrolocytosine derivative of this invention markedly increased PNA oligomer's affinity for complementary DNA.
- Oligo 10 having three 'modified' cytosine 'C(1O2)' monomers showed a T m exceeding 85 0 C, while the corresponding 'unmodified' Oligo 11 showed a T m of 58 0 C.
- Other modified cytosine monomers such as 'C(1O3)' or 'C(2O2)' also significantly increased PNA oligomer's affinity for complementary DNA, as exemplified with Oligo 3 and Oligo 8.
- 'Modified' adenine nucleobases of this invention also significantly increased PNA oligomer's affinity for complementary DNA.
- Oligo 15 having four 'modified' adenine A(7) monomers showed a T m of 71 0 C, which is significantly higher than the T m of 55 0 C observed with 'unmodified' Oligo 27.
- Other 'modified' adenine monomers such as A(4), and A(5) also markedly increased affinity for complementary DNA.
- 'Modified' PNA monomers of this invention were found to be quite sensitive to base mismatch. For example, decreases of 11 ⁇ 14 0 C in T m were observed with single base mismatches for an A(5) monomer in Oligo 17. Single base mismatches for a C(1O2) monomer in Oligo 20 resulted in decreases of 19 ⁇ 22 0 C in T m .
- Figure 4(a) and 4(b) are provided confocal microscopy images (at 63x objective) I 1 2, 3 and 24h after HeLa cells were treated with Oliqo 1 and Oliqo 2 at 5 ⁇ M, respectively (without FBS). While fluorescence intensity is clear and becomes intense over 24h in Figure 4(a), fluorescence intensity is faint in Figure 4(b), indicating that Oliqo 1 penetrates HeLa cells significantly faster than 'unmodified' Qliqo 2.
- Figure 5(a) and 5(b) are provided confocal microscopy images (at 63x objective) 0.5 and Ih after MCF-7 cells were treated with Oliqo 6 and Oliqo 7 at 2.5 ⁇ M, respectively (without FBS).
- Figure 7(a) and 7(b) are provided confocal microscopy pictures (4Ox objective) 24h after JAR cells were treated with Oliqo 21 and Oliqo 28 at 2 ⁇ M, respectively (without FBS). While fluorescence intensity is strong in Figure 7(a), there is no significant fluorescence intensity in Figure 7(b), suggesting that Oliqo 21 penetrate JAR cells significantly faster than 'unmodified' Oliqo 28.
- Figure 7(c) and 7(d) are provided confocal microscopy pictures (at 4Ox objective) 24h after A549 cells were treated with Oliqo 21 and Qliqo 28 at 2 ⁇ M, respectively (without FBS).
- Figure 7(g) are provided confocal microscopy pictures (at 4Ox objective) 24h after HeLa cells were treated with Oliqo 21 at 2 ⁇ M (without FBS). Given that the celluar fluorescence in Figure 7(g) is significantly stronger than that in Figure 7(e), Oligo 21 appears to penetrate over 24h rather than 12h.
- Figure 8(a), 8(b) and 8(c) provide confocal microscopy images (40x objective) 24h after HeLa, A549, and JAR cells were treated with 2 ⁇ M Oliqo 22, respectively (without FBS). All the images are associated with fluorescence within cell, indicating that Oliqo 22 possesses good cell penetration in the tested cells.
- Oliqo 9 and Oliqo 12 possess the same base sequences as Tl-12 and T5-12, respectively, which were reported to inhibit the ribosomal synthesis of mdm2 in the literature. ⁇ Nucleic Acids Res. vol 32, 4893-4902, 2004) Oliqo 9 and Oliqo 12 were evaluated for their ability to inhibit the ribosomal synthesis of mdm2 in JAR cells as follows. The following antisense example is presented for illustrative purposes only and should not be interpreted as a restriction to the present invention.
- JAR cells (ATCC catalog # HTB-144) were grown in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin at 37 0 C and 5% CO 2 . Cells were then seeded into each well of a 12-well plate containing ImI of the same medium, and treated with an aliquot of an aqueous stock solution of Oliqo 9 or Oliqo 12 of a designated concentration. Then the cells were incubated at 37 0 C and 5% CO 2 for 15h. The cells in each well were washed with cold PBS and treated with 80 ⁇ l RIPA buffer containing 1% protease inhibitors cocktail, and the plate was incubated at 4 0 C and agitated slowly for 15min.
- each well was scraped out into a microtube.
- the microtube was incubated in ice for lOmin and centrifuged at 10,000g.
- the resulting supernatant was collected and subjected to protein quantification by Bradford assay and western blot analysis.
- 20 ⁇ g of protein was loaded onto each lane of the gel in a minigel apparatus, separated and transferred onto a PVDF membrane (0.45 ⁇ , Millipore).
- the primary mdm2 antibody used for western blotting was SC-965 (Santa Cruz Biotechnology).
- Figure 9 provides western blotting results for JAR cells treated with 5 ⁇ M or 10 ⁇ M Oliqo 9, 5 ⁇ M or 10 ⁇ M Oliqo 10, cotreatment with the oligomers at 5 ⁇ M or 10 ⁇ M each, and blank (no oligomer treatment).
- treatment with Oliqo 9 or Oliqo 10 or cotreatment with Oliqo 9 and Oliqo 10 significantly inhibited ribosomal synthesis of mdm2 in JAR cells both at 5 ⁇ M and 10 ⁇ M.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (23)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/922,322 US8680253B2 (en) | 2008-03-14 | 2009-03-13 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid |
RU2010135635/04A RU2564032C2 (en) | 2008-03-14 | 2009-03-13 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid |
MX2010009687A MX2010009687A (en) | 2008-03-14 | 2009-03-13 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid. |
KR1020107018868A KR101598423B1 (en) | 2008-03-14 | 2009-03-13 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid |
DK09719041.7T DK2268607T5 (en) | 2008-03-14 | 2009-03-13 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRENGTH AFFINITY OF NUCLEIC ACID |
PL09719041T PL2268607T3 (en) | 2008-03-14 | 2009-03-13 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid |
CN200980109059.1A CN102015628B (en) | 2008-03-14 | 2009-03-13 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid |
CA2715844A CA2715844C (en) | 2008-03-14 | 2009-03-13 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid |
NZ587448A NZ587448A (en) | 2008-03-14 | 2009-03-13 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid |
AU2009224149A AU2009224149B2 (en) | 2008-03-14 | 2009-03-13 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid |
EP20090719041 EP2268607B9 (en) | 2008-03-14 | 2009-03-13 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid |
ES09719041.7T ES2533769T3 (en) | 2008-03-14 | 2009-03-13 | Derivatives of peptide nucleic acids with good cell penetration and strong affinity for nucleic acid |
BRPI0906104A BRPI0906104B8 (en) | 2008-03-14 | 2009-03-13 | peptonucleic acid derivative, pharmaceutical composition containing a therapeutically effective amount of the peptonucleic acid derivative, method of using the peptonucleic acid derivative and compound |
JP2010550603A JP5620282B2 (en) | 2008-03-14 | 2009-03-13 | Peptide nucleic acid derivatives with excellent cell permeability and strong nucleic acid affinity |
IL207617A IL207617A (en) | 2008-03-14 | 2010-08-15 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid |
ZA2010/05960A ZA201005960B (en) | 2008-03-14 | 2010-08-20 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid |
HK11109665.2A HK1155717A1 (en) | 2008-03-14 | 2011-09-14 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid |
US14/109,327 US8884008B2 (en) | 2008-03-14 | 2013-12-17 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid |
US14/133,045 US8859766B2 (en) | 2008-03-14 | 2013-12-18 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid |
US14/134,279 US8895734B2 (en) | 2008-03-14 | 2013-12-19 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid |
IL236514A IL236514A0 (en) | 2008-03-14 | 2014-12-30 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid |
IL236515A IL236515A0 (en) | 2008-03-14 | 2014-12-30 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid |
IL236513A IL236513A0 (en) | 2008-03-14 | 2014-12-30 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2008-23658 | 2008-03-14 | ||
KR20080023658 | 2008-03-14 | ||
KR10-2008-111459 | 2008-11-11 | ||
KR20080111459 | 2008-11-11 |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/922,322 A-371-Of-International US8680253B2 (en) | 2008-03-14 | 2009-03-13 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid |
US14/109,327 Division US8884008B2 (en) | 2008-03-14 | 2013-12-17 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid |
US14/133,045 Division US8859766B2 (en) | 2008-03-14 | 2013-12-18 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid |
US14/134,279 Division US8895734B2 (en) | 2008-03-14 | 2013-12-19 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2009113828A2 true WO2009113828A2 (en) | 2009-09-17 |
WO2009113828A9 WO2009113828A9 (en) | 2009-11-05 |
WO2009113828A3 WO2009113828A3 (en) | 2009-12-23 |
Family
ID=41065678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2009/001256 WO2009113828A2 (en) | 2008-03-14 | 2009-03-13 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid |
Country Status (19)
Country | Link |
---|---|
US (4) | US8680253B2 (en) |
EP (1) | EP2268607B9 (en) |
JP (1) | JP5620282B2 (en) |
KR (2) | KR20090098710A (en) |
CN (1) | CN102015628B (en) |
AU (1) | AU2009224149B2 (en) |
BR (1) | BRPI0906104B8 (en) |
CA (1) | CA2715844C (en) |
DK (1) | DK2268607T5 (en) |
ES (1) | ES2533769T3 (en) |
HK (1) | HK1155717A1 (en) |
IL (4) | IL207617A (en) |
MX (1) | MX2010009687A (en) |
NZ (1) | NZ587448A (en) |
PL (1) | PL2268607T3 (en) |
PT (1) | PT2268607E (en) |
RU (1) | RU2564032C2 (en) |
WO (1) | WO2009113828A2 (en) |
ZA (1) | ZA201005960B (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011047319A3 (en) * | 2009-10-16 | 2011-08-18 | Rib-X Pharmaceuticals, Inc. | Antimicrobial compounds and methods of making and using the same |
US9221827B2 (en) | 2011-04-15 | 2015-12-29 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
JP2016172733A (en) * | 2009-10-16 | 2016-09-29 | メリンタ セラピューティクス,インコーポレイテッド | Antimicrobial compounds and methods of making and using antimicrobial compounds |
US9573962B2 (en) | 2009-10-16 | 2017-02-21 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
US9845297B2 (en) | 2009-10-16 | 2017-12-19 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
WO2018029517A1 (en) | 2016-08-08 | 2018-02-15 | Olipass Corporation | Androgen receptor antisense oligonucleotides |
WO2018051175A1 (en) | 2016-09-16 | 2018-03-22 | Olipass Corporation | Scn9a antisense oligonucleotides |
US9937183B2 (en) | 2013-09-09 | 2018-04-10 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
WO2018091544A1 (en) | 2016-11-16 | 2018-05-24 | Biomarin Pharmaceutical, Inc. | Substances for targeting various selected organs or tissues |
WO2018122610A1 (en) * | 2016-12-30 | 2018-07-05 | Olipass Corporation | Exon skipping by peptide nucleic acid derivatives |
WO2018127733A1 (en) * | 2017-01-06 | 2018-07-12 | Olipass Corporation | Snap25 antisense oligonucleotides |
WO2018138585A1 (en) * | 2017-01-24 | 2018-08-02 | Olipass Corporation | Scn9a antisense pain killer |
US10106543B2 (en) | 2013-09-09 | 2018-10-23 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
WO2019022434A1 (en) * | 2017-07-24 | 2019-01-31 | Olipass Corporation | Tyrosinase antisense oligonucleotides |
WO2019221570A1 (en) * | 2018-05-18 | 2019-11-21 | Olipass Corporation | Matrix metalloproteinase-1 antisense oligonucleotides |
WO2020036353A1 (en) | 2018-08-14 | 2020-02-20 | Olipass Corporation | Acetyl-coa carboxylase2 antisense oligonucleotides |
EP3526239A4 (en) * | 2016-10-11 | 2020-07-29 | Olipass Corporation | Hif 1-alpha antisense oligonucleotides |
WO2021010723A1 (en) * | 2019-07-18 | 2021-01-21 | OLIPASS Cosmeceuticals Company | Melanophilin antisense oligonucleotides |
US10947237B2 (en) | 2015-03-11 | 2021-03-16 | BioVersys AG | Antimicrobial compounds and methods of making and using the same |
RU2778786C2 (en) * | 2017-07-24 | 2022-08-24 | Олипасс Корпорейшн | Antisense tyrosinase oligonucleotides |
TWI782999B (en) * | 2017-07-24 | 2022-11-11 | 韓商奧利通公司 | Tyrosinase antisense oligonucleotides |
US11999739B2 (en) | 2016-05-06 | 2024-06-04 | BioVersys AG | Antimicrobials methods of making and using the same |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9234059B2 (en) | 2008-07-16 | 2016-01-12 | Outlast Technologies, LLC | Articles containing functional polymeric phase change materials and methods of manufacturing the same |
US8221910B2 (en) | 2008-07-16 | 2012-07-17 | Outlast Technologies, LLC | Thermal regulating building materials and other construction components containing polymeric phase change materials |
CN103031337A (en) * | 2012-09-28 | 2013-04-10 | 北京吉利奥生物科技发展有限公司 | Small nucleic acid molecule delivery technology |
AU2016341208A1 (en) * | 2015-10-20 | 2018-05-10 | Sorrento Therapeutics, Inc. | Intracellular delivery compounds |
KR20210151593A (en) | 2020-06-05 | 2021-12-14 | 넥스올리고(주) | Novel Morpholino Oligonucleotide derivatives |
KR102633299B1 (en) * | 2023-09-08 | 2024-02-02 | 국방과학연구소 | A pharmaceutical composition for the treatment of Hantaan virus infectious disease containing a cell-permeable peptide nucleic acid oligomer as an active ingredient |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK51092D0 (en) | 1991-05-24 | 1992-04-15 | Ole Buchardt | OLIGONUCLEOTIDE ANALOGUE DESCRIBED BY PEN, MONOMERIC SYNTHONES AND PROCEDURES FOR PREPARING THEREOF, AND APPLICATIONS THEREOF |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US6133444A (en) | 1993-12-22 | 2000-10-17 | Perseptive Biosystems, Inc. | Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions |
US6617422B1 (en) * | 1997-05-23 | 2003-09-09 | Peter Nielsen | Peptide nucleic acid monomers and oligomers |
DE10019136A1 (en) * | 2000-04-18 | 2001-10-31 | Aventis Pharma Gmbh | Polyamide nucleic acid derivatives, agents and processes for their preparation |
CN1814614A (en) * | 2005-02-06 | 2006-08-09 | 中国人民解放军军事医学科学院毒物药物研究所 | Nucleic acid, peptide nucleicacid derivatives and their use |
WO2008061091A2 (en) | 2006-11-13 | 2008-05-22 | Grandis Jennifer R | Antisense guanidinium peptide nucleic acid (gpna) oligonucleotides as antitumor agents |
-
2009
- 2009-03-12 KR KR1020090021040A patent/KR20090098710A/en not_active Application Discontinuation
- 2009-03-13 RU RU2010135635/04A patent/RU2564032C2/en active
- 2009-03-13 EP EP20090719041 patent/EP2268607B9/en active Active
- 2009-03-13 PL PL09719041T patent/PL2268607T3/en unknown
- 2009-03-13 BR BRPI0906104A patent/BRPI0906104B8/en active IP Right Grant
- 2009-03-13 CN CN200980109059.1A patent/CN102015628B/en active Active
- 2009-03-13 DK DK09719041.7T patent/DK2268607T5/en active
- 2009-03-13 MX MX2010009687A patent/MX2010009687A/en active IP Right Grant
- 2009-03-13 NZ NZ587448A patent/NZ587448A/en unknown
- 2009-03-13 US US12/922,322 patent/US8680253B2/en active Active
- 2009-03-13 ES ES09719041.7T patent/ES2533769T3/en active Active
- 2009-03-13 AU AU2009224149A patent/AU2009224149B2/en active Active
- 2009-03-13 WO PCT/KR2009/001256 patent/WO2009113828A2/en active Application Filing
- 2009-03-13 JP JP2010550603A patent/JP5620282B2/en active Active
- 2009-03-13 PT PT97190417T patent/PT2268607E/en unknown
- 2009-03-13 CA CA2715844A patent/CA2715844C/en active Active
- 2009-03-13 KR KR1020107018868A patent/KR101598423B1/en active IP Right Grant
-
2010
- 2010-08-15 IL IL207617A patent/IL207617A/en active IP Right Grant
- 2010-08-20 ZA ZA2010/05960A patent/ZA201005960B/en unknown
-
2011
- 2011-09-14 HK HK11109665.2A patent/HK1155717A1/en unknown
-
2013
- 2013-12-17 US US14/109,327 patent/US8884008B2/en active Active
- 2013-12-18 US US14/133,045 patent/US8859766B2/en active Active
- 2013-12-19 US US14/134,279 patent/US8895734B2/en active Active
-
2014
- 2014-12-30 IL IL236513A patent/IL236513A0/en active IP Right Grant
- 2014-12-30 IL IL236515A patent/IL236515A0/en active IP Right Grant
- 2014-12-30 IL IL236514A patent/IL236514A0/en active IP Right Grant
Non-Patent Citations (3)
Title |
---|
J. AM. CHEM. SOC., vol. 130, 2008, pages 12574 - 12575 |
NUCLEIC ACIDS RES., vol. 25, 1997, pages 4639 - 4643 |
ORG. LETT., vol. 4, 2002, pages 4395 - 4398 |
Cited By (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI612048B (en) * | 2009-10-16 | 2018-01-21 | 梅林塔療法公司 | Antimicrobial compounds and methods of making and using the same |
TWI629277B (en) * | 2009-10-16 | 2018-07-11 | 梅林塔療法公司 | Antimicrobial compounds and methods of making and using the same |
JP2013508297A (en) * | 2009-10-16 | 2013-03-07 | リブ−エックス ファーマシューティカルズ,インコーポレイテッド | Antimicrobial compounds and methods of making and using antimicrobial compounds |
US9193731B2 (en) | 2009-10-16 | 2015-11-24 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
KR20170132900A (en) * | 2009-10-16 | 2017-12-04 | 멜린타 테라퓨틱스, 인크. | Antimicrobial compounds and methods of making and using the same |
AU2010306646B2 (en) * | 2009-10-16 | 2016-09-01 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
JP2016172733A (en) * | 2009-10-16 | 2016-09-29 | メリンタ セラピューティクス,インコーポレイテッド | Antimicrobial compounds and methods of making and using antimicrobial compounds |
CN108456211A (en) * | 2009-10-16 | 2018-08-28 | 梅琳塔治疗公司 | Antimicrobe compound and its preparation and application |
US10259825B2 (en) | 2009-10-16 | 2019-04-16 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
CN102712647A (en) * | 2009-10-16 | 2012-10-03 | Rib-X制药公司 | Antimicrobial compounds and methods of making and using the same |
US9573962B2 (en) | 2009-10-16 | 2017-02-21 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
US9845297B2 (en) | 2009-10-16 | 2017-12-19 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
TWI618707B (en) * | 2009-10-16 | 2018-03-21 | 梅林塔療法公司 | Antimicrobial compounds and methods of making and using the same |
KR101972992B1 (en) * | 2009-10-16 | 2019-04-29 | 멜린타 서브시디어리 코프. | Antimicrobial compounds and methods of making and using the same |
WO2011047319A3 (en) * | 2009-10-16 | 2011-08-18 | Rib-X Pharmaceuticals, Inc. | Antimicrobial compounds and methods of making and using the same |
US9221827B2 (en) | 2011-04-15 | 2015-12-29 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
US9937183B2 (en) | 2013-09-09 | 2018-04-10 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
US10106543B2 (en) | 2013-09-09 | 2018-10-23 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
US10947237B2 (en) | 2015-03-11 | 2021-03-16 | BioVersys AG | Antimicrobial compounds and methods of making and using the same |
US11999739B2 (en) | 2016-05-06 | 2024-06-04 | BioVersys AG | Antimicrobials methods of making and using the same |
KR20190055066A (en) * | 2016-08-08 | 2019-05-22 | 올리패스 주식회사 | Androgen receptor antisense oligonucleotides |
AU2017309347B2 (en) * | 2016-08-08 | 2020-11-19 | Olipass Corporation | Androgen receptor antisense oligonucleotides |
WO2018029517A1 (en) | 2016-08-08 | 2018-02-15 | Olipass Corporation | Androgen receptor antisense oligonucleotides |
KR102427575B1 (en) | 2016-08-08 | 2022-08-01 | 올리패스 주식회사 | Androgen receptor antisense oligonucleotides |
CN109996807A (en) * | 2016-09-16 | 2019-07-09 | 奥利通公司 | SCN9A antisense oligonucleotides |
KR20190043175A (en) * | 2016-09-16 | 2019-04-25 | 올리패스 주식회사 | SCN9A Antisense Oligonucleotides |
KR102443631B1 (en) | 2016-09-16 | 2022-09-15 | 올리패스 주식회사 | SCN9A Antisense Oligonucleotides |
WO2018051175A1 (en) | 2016-09-16 | 2018-03-22 | Olipass Corporation | Scn9a antisense oligonucleotides |
CN109996807B (en) * | 2016-09-16 | 2023-07-28 | 奥利通公司 | SCN9A antisense oligonucleotides |
US11319540B2 (en) | 2016-10-11 | 2022-05-03 | Olipass Corporation | HIF 1-alpha antisense oligonucleotides |
EP3526239A4 (en) * | 2016-10-11 | 2020-07-29 | Olipass Corporation | Hif 1-alpha antisense oligonucleotides |
WO2018091544A1 (en) | 2016-11-16 | 2018-05-24 | Biomarin Pharmaceutical, Inc. | Substances for targeting various selected organs or tissues |
US11459358B2 (en) | 2016-11-16 | 2022-10-04 | Academisch Ziekenhuis Leiden | Substances for targeting various selected organs or tissues |
WO2018122610A1 (en) * | 2016-12-30 | 2018-07-05 | Olipass Corporation | Exon skipping by peptide nucleic acid derivatives |
RU2786637C2 (en) * | 2016-12-30 | 2022-12-23 | Олипасс Корпорейшн | Exon skip with peptidonucleic acid derivatives |
CN110506051A (en) * | 2016-12-30 | 2019-11-26 | 奥利通公司 | Pass through the exon skipping of peptide nucleic acid derivatives |
AU2017390396B2 (en) * | 2017-01-06 | 2021-03-25 | Olipass Corporation | SNAP25 antisense oligonucleotides |
WO2018127733A1 (en) * | 2017-01-06 | 2018-07-12 | Olipass Corporation | Snap25 antisense oligonucleotides |
US11261448B2 (en) | 2017-01-06 | 2022-03-01 | Olipass Corporation | SNAP25 antisense oligonucleotides |
RU2766701C2 (en) * | 2017-01-06 | 2022-03-15 | Олипасс Корпорейшн | Antisense oligonucleotides for snap25 |
RU2762293C2 (en) * | 2017-01-24 | 2021-12-17 | Олипасс Корпорейшн | Antisense analgesic for scn9a |
AU2018213153B2 (en) * | 2017-01-24 | 2021-04-01 | Olipass Corporation | SCN9A antisense pain killer |
WO2018138585A1 (en) * | 2017-01-24 | 2018-08-02 | Olipass Corporation | Scn9a antisense pain killer |
US11162104B2 (en) | 2017-01-24 | 2021-11-02 | Olipass Corporation | SCN9A antisense pain killer |
RU2778786C2 (en) * | 2017-07-24 | 2022-08-24 | Олипасс Корпорейшн | Antisense tyrosinase oligonucleotides |
RU2778786C9 (en) * | 2017-07-24 | 2022-10-14 | Олипасс Корпорейшн | Tyrosinase antisense oligonucleotides |
TWI782999B (en) * | 2017-07-24 | 2022-11-11 | 韓商奧利通公司 | Tyrosinase antisense oligonucleotides |
WO2019022434A1 (en) * | 2017-07-24 | 2019-01-31 | Olipass Corporation | Tyrosinase antisense oligonucleotides |
WO2019221570A1 (en) * | 2018-05-18 | 2019-11-21 | Olipass Corporation | Matrix metalloproteinase-1 antisense oligonucleotides |
WO2020036353A1 (en) | 2018-08-14 | 2020-02-20 | Olipass Corporation | Acetyl-coa carboxylase2 antisense oligonucleotides |
US11739124B2 (en) | 2018-08-14 | 2023-08-29 | Olipass Corporation | Acetyl-CoA carbosylase2 antisense oligonucleotides |
WO2021010723A1 (en) * | 2019-07-18 | 2021-01-21 | OLIPASS Cosmeceuticals Company | Melanophilin antisense oligonucleotides |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2268607T5 (en) | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRENGTH AFFINITY OF NUCLEIC ACID | |
US10093700B2 (en) | Conformationally-preorganized, MiniPEG-containing gamma-peptide nucleic acids | |
US8859490B2 (en) | Peptide nucleic acid monomers and oligomers | |
US20100317593A1 (en) | 2,3-dihydro-1h-indene compounds | |
Jain | Cγ-Aminopropylene peptide nucleic acid (amp-PNA): Chiral cationic PNAs with superior PNA: DNA/RNA duplex stability and cellular uptake | |
CA2281843A1 (en) | Stereochemical control of the dna binding affinity, sequence specificity, and orientation-preference of chiral hairpin polyamides in the minor groove | |
US7745473B2 (en) | Indole derivative for alkylating specific base sequence of DNA and alkylating agent and drug containing the derivative | |
US7498405B2 (en) | Halogen-substituted thienyl compounds | |
US20230235328A1 (en) | Novel morpholino oligonucleotide derivatives | |
CN110526915B (en) | Preparation method of anaplastic lymphoma kinase inhibitor | |
Gokhale et al. | Amino/guanidino-functionalized N-(pyrrolidin-2-ethyl) glycine-based pet-PNA: Design, synthesis and binding with DNA/RNA | |
JP2003219874A (en) | Method for using peptide nucleic acid selectively binding to rna as antisense oligonucleotide, and method for producing the peptide nucleic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980109059.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09719041 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 207617 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2715844 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 587448 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009224149 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 20107018868 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010135635 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2010/009687 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2009224149 Country of ref document: AU Date of ref document: 20090313 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009719041 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12922322 Country of ref document: US Ref document number: 2010550603 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6717/DELNP/2010 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: PI0906104 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100913 |